Items tagged with Scientific research

Scripps Florida scientists discover new compounds with potential to treat persistent tuberculosis (post)

JUPITER, FL – November 17, 2015 – Tuberculosis has been infecting humans for several millennia, making it one of the most horribly successful diseases in history. Today, it is still a major killer, responsible for some 1.5 million deaths each year.

Tuberculosis: Daily antibiotics recommended to prevent resistant strains (post)

A computer model of tuberculosis has shown that approved treatments prescribing antibiotic doses once or twice a week are more likely to lead to drug resistant strains than are daily antibiotic regimens.

Developing drug resistance may be a matter of diversity for tuberculosis (post)

To a microbe, the human body is a vast environment, full of resources and opportunities, dangers and threats. In the world of bacteria, it's thrive or fail to survive. Evolve or go extinct.

Deadly protein that causes TB identified, can help develop novel therapies to treat the disease (post)

Scientists at the Centre for DNA Fingerprinting and Diagnostics (CDFD) have discovered a protein that causes mycobacterium tuberculosis. This discovery could help develop therapies to treat tuberculosis.

Scientists use breakthrough DNA technology to diagnose cases of TB faster (post)

Whole Genome Sequencing is a faster, cheaper and more effective way of diagnosing tuberculosis says a new study published in the journal Lancet Respiratory Medicine.

Dr Louise Pankhurst of the University of Oxford and a team of worldwide collaborators including Public Health England utilised innovative DNA technology to diagnose cases of tuberculosis (TB) up to eight times faster than traditional methods. 

OHSU Doernbecher awarded $3 million to advance tuberculosis vaccine research (post)

December 7, 2015 - Researchers at Oregon Health & Science University have been awarded a $3 million grant from the Bill & Melinda Gates Foundation to study whether a particular group of infection-fighting cells, known as T cells, may be viable for the development of a vaccine aimed at combatting the global tuberculosis epidemic.

$5 million in funding for research into malaria and tuberculosis drug discovery (post)

December 17, 2015 - University of Toronto and McGill University scientists are leading an international partnership to discover new and improved drug treatments for tuberculosis, malaria and neglected tropical diseases -- thanks to a contribution from Merck Canada Inc., as well as an additional $5 million supplement to a grant from the Bill & Melinda Gates Foundation. The new funding brings the total investment from the Bill & Melinda Gates Foundation to nearly US $12 million since 2012.

La Jolla Institute for Allergy and Immunology team receives $18 million consortium grant (post)

LA JOLLA, CA, December 17, 2015 - The La Jolla Institute for Allergy and Immunology (LJI) is pleased to announce that an international team led by LJI investigator Alessandro Sette, Ph.D., is one of four recipients of a Human Immune Profiling Consortium (HIPC) grant in 2015. With this prestigious grant, the LJI team will characterize the immune response to dengue virus (DENV) and Mycobacterium tuberculosis (TB), both of which represent major global health challenges.

Plant-based drug can fight resistant TB (post)

• New compounds work by disabling a protective enzyme produced by TB bugs
• The compounds originate from the ellipticine plant-alkaloid family
• Both dormant and highly drug-resistant TB bugs can be dealt with

BANGALORE, December 20, 2015 - Scientists from India and the US say they have discovered a group of compounds that can kill Mycobacterium tuberculosis, the bacterium responsible for causing tuberculosis (TB), by disabling a major defence mechanism it uses to survive in the human body.

Phase 1 TBA-354 placed on clinical hold (post)

January 4, 2016 - TB Alliance announced today that it has voluntarily halted further dosing of TBA-354 in the ongoing Multiple Ascending Dose (MAD) Phase 1 study. This action has prompted the United States Food and Drug Administration (FDA) to place the organization’s Investigational New Drug (IND) submission for TBA-354 on clinical hold. TBA-354, which had entered Phase 1 testing in early 2015, is from the nitroimidazole class of chemicals.